BBH:NSD-VanEck Biotech ETF (USD)

ETF | Health |

Last Closing

USD 180.65

Change

-0.21 (-0.12)%

Market Cap

USD 0.46B

Volume

4.40K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

-0.31 (-0.21%)

USD 7.64B
PPH VanEck Pharmaceutical ETF

-0.09 (-0.09%)

USD 0.73B
PSCH Invesco S&P SmallCap Health Ca..

+0.10 (+0.22%)

USD 0.20B
PTH Invesco DWA Healthcare Momentu..

+0.25 (+0.54%)

USD 0.15B
GNOM Global X Genomics & Biotechnol..

-0.09 (-0.79%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.05 (-0.15%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.25 (-1.60%)

USD 0.01B

ETFs Containing BBH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.28% 50% F 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.28% 50% F 66% D+
Trailing 12 Months  
Capital Gain 13.87% 38% F 64% D
Dividend Return 0.45% 67% D+ 5% F
Total Return 14.32% 38% F 61% D-
Trailing 5 Years  
Capital Gain 46.04% 75% C 72% C
Dividend Return 2.38% 57% F 7% C-
Total Return 48.41% 63% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 4.61% 63% D 57% F
Dividend Return 4.98% 63% D 54% F
Total Return 0.37% 63% D 11% F
Risk Return Profile  
Volatility (Standard Deviation) 19.84% 75% C 77% C+
Risk Adjusted Return 25.11% 75% C 59% D-
Market Capitalization 0.46B 75% C 60% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike